Of the 132 enrolled patients, KRAS, NRAS, BRAFV600E, and MSI status was available in 62 (47%), 57 (43.2%), 54 (40.9%), and 62 (47%) CRC patients, respectively (Table S1). This evidence concerns the gene KRAS and colorectal carcinoma.